Importance Coronavirus disease 2019 (COVID-19) may lead to serious illness as a result of
an excessive immune response. Fluvoxamine may prevent clinical deterioration by …

Importance The effect of higher-dose fluvoxamine in reducing symptom duration among
outpatients with mild to moderate COVID-19 remains uncertain. Objective To assess the …

Importance The effectiveness of fluvoxamine to shorten symptom duration or prevent
hospitalization among outpatients with mild to moderate symptomatic COVID-19 is unclear …

SARS-CoV-2 infection causes COVID-19, which frequently leads to clinical deterioration
and/or long-lasting morbidity. Academic and governmental experts throughout the USA met …

Background Recent evidence indicates a potential therapeutic role of fluvoxamine for
COVID-19. In the TOGETHER trial for acutely symptomatic patients with COVID-19, we …

Importance Widely available and affordable options for the outpatient management of
COVID-19 are needed, particularly for therapies that prevent hospitalization. Objective To …

Aims Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI) and sigma‐1 receptor
agonist, has so far shown promise in the prevention of COVID‐19 progression as an early …

Background: Previous trials have demonstrated the effects of fluvoxamine alone and inhaled
budesonide alone for prevention of disease progression among outpatients with COVID-19 …

We report a real-world experience using fluvoxamine for coronavirus disease 19 (COVID-
19) in a prospective cohort in the setting of a mass outbreak. Overall, 65 persons opted to …

Fluvoxamine is a well-tolerated, widely available, inexpensive selective serotonin reuptake
inhibitor that has been shown in a small, double-blind, placebo-controlled, randomized …